Optimizing Pharma IP Processes
This case study demonstrates Seprotec's collaboration with a top global pharmaceutical business to expedite intellectual property processes and reduce translation expenses.
Seprotec offered a comprehensive IP management system, increasing productivity and generating considerable cost savings through the centralization and optimization of translation and European Patent Validation processes.
-
Objective
To reduce the considerable translation costs associated with European patent validation cases while improving efficiency, transparency and control of intellectual property management processes.
-
Challenge
The client was was facing increasing annual translation expenditure while undertaking a global cost-reduction initiative.
Additional challenges included a lack of linguistic assets such as translation memories and glossaries, the absence of an in-house IP translation department, uncertainty around outsourced translation processes, and the need to reduce administrative workloads so that internal teams could focus on higher-value activities. -
Implementation
Seprotec implemented a comprehensive IP management solution combining in-house patent translation services, formalities management, global IP administration and access to a worldwide network of trusted IP agents.
The solution included the creation of translation memories and glossaries, deployment of the SHIP Helm IP management platform, integration with the client’s document management systems, real-time project tracking, centralized reporting, country-specific legal support and a structured savings program. -
Result
Following a rigorous selection process, Seprotec was appointed as the sole provider for the service.
The implementation generated increasing savings through translation memory optimization, rising from 14% to 27.6% over the course of the partnership. Additional benefits included greater transparency, streamlined administration, improved consistency, centralized IP management, enhanced reporting capabilities and long-term cost reductions in European patent validation activities.